This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:

BMS Reports the Updated Data from P-III (CheckMate -73L) Study of Opdivo for Non-Small Cell Lung Cancer

Read More: BMS                                                                                     

HUTCHMED Commences the P-III (RAPHAEL) Study of HMPL-306 for Treating Acute Myeloid Leukemia in China

Read More: HUTCHMED                               

HUTCHMED Commences the P-II/III Study of Surufatinib Plus Camrelizumab for Pancreatic Ductal Adenocarcinoma

Read More: HUTCHMED                                                                                            

Ocugen Concludes Dosing in Cohort 2 of the P-I/II Study Evaluating OCU410ST for Stargardt Disease

Read More: Ocugen                                                                            

Roche Reveals Results from the P-I Clinical Evaluation of CT-388 for Treating Obesity and Type 2 Diabetes

Read More: Roche                                                                

Eli Lilly Reports Data from Two P-III (QWINT-2 and QWINT-4) Studies of Efsitora for Treating Type 2 Diabetes

Read More: Eli Lilly                                                                                                  

BMS Reports Results from the P-III (POETYK PSO) Long-Term Extension Study of Sotyktu for Treating Plaque Psoriasis

Read More: BMS                                                                                          

HUTCHMED Reports the P-III Trial Data and will Highlight Hematological Malignancy Programs at the EHA 2024

Read More: HUTCHMED                                                                                    

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent to Treat Chronic Rhinosinusitis with Nasal Polyposis (CRSWNP)

Read More: Regeneron & Sanofi                                                                      

Zai Lab’s Augtyro Receives the NMPA’s Approval to Treat Non-Small-Cell Lung Cancer (NSCLC)

Read More: Zai Lab                                                                                                     

Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma

Read More: Meru                                                                  

Roche Receives the US FDA’s Approval for HPV Self-Collection Solutions for Cervical Cancer

Read More: Roche                                                                                               

The US FDA Rejects Dynavax’ Four-Dose Heplisav-B Regimen for Adults on Hemodialysis

Read More: Dynavax                                                                                           

BMS Reports the US FDA’s Accelerated Approval of Breyanzi for Treating Follicular Lymphoma (FL)

Read More: BMS                                                                                           

Amgen’s Imdelltra (Tarlatamab-dlle) Receives the US FDA’s Approval to Treat Extensive-Stage Small Cell Lung Cancer

Read More: Amgen                 

Fulcrum Therapeutics Partners with Sanofi to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy

Read More: Fulcrum Therapeutics & Sanofi                                                        

Takeda and AC Immune Collaborate for ACI-24.060 to Treat Alzheimer’s Disease

Read More: Takeda & AC Immune                                                                           

AbbVie Partners with Gilgamesh Pharmaceuticals to Develop Next-Generation Therapies for Psychiatric Disorders

Read More: AbbVie & Gilgamesh Pharmaceuticals                                             

Sol-Gel Technologies and Beimei Pharma Collaborate to Commercialize Twyneo for Treating Acne Vulgaris

Read More: Sol-Gel Technologies & Beimei Pharma                                         

QIAGEN’s QIAstat-Dx Respiratory Syndromic Testing Panel Gains the US FDA’s Clearance to Diagnose Upper Respiratory Infections

Read More: QIAGEN                                                                                              

Profound Medical’s Contouring Assistant AI Module Gains the US FDA’s Approval for Creating Automated TULSA Treatment Plan

Read More: Profound Medical                                                                             

Atraverse Medical Reports the US FDA’s Clearance of Hotwire Left Heart Access Device

Read More: Atraverse Medical                                                                     

Karius Reports the US FDA’s Breakthrough Device Designation for its Karius Test to Diagnose Infectious Disease

Read More: Karius                                                                                                 

Johnson & Johnson to Expand its Dermatology Portfolio Through the Acquisition of Proteologix

Read More: Johnson & Johnson                                                                              

Merck Animal Health to Feature Innovative Solutions Focusing Ruminant Health at the World Buiatrics Congress 2024

Read More: Merck Animal Health                                                                     

Boehringer Ingelheim Introduces Bultavo 3 Vaccine Against Bluetongue Virus Serotype 3 for Sheep and Cattle

Read More: Boehringer Ingelheim                                                                             

Ainos to Commence Clinical Trial of Veldona-Based Drugs for Treating Pet Disease

Read More: Ainos                           

Boehringer Ingelheim Partners with Quallent Pharmaceuticals to Expand the Access of Cyltezo (Biosimilar, Humira)

Read More: Boehringer Ingelheim & Quallent Pharmaceuticals                    

AstraZeneca Reports Results from the P-III (SUPERNOVA) Study of Sipavibart to Prevent COVID-19 in Immunocompromised Patients

Read More: AstraZeneca                                                                                       

Azitra Highlights Preclinical Results and P-Ib Clinical Design of ATR-12 for Netherton Syndrome at the ASGCT 2024

Read More: Azitra        

Related Post:- PharmaShots Weekly Snapshots (May 06 – May 10, 2024)